The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.00
Bid: 1.93
Ask: 2.00
Change: 0.10 (5.26%)
Spread: 0.07 (3.627%)
Open: 1.80
High: 2.00
Low: 1.80
Prev. Close: 1.90
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Gore Street Energy Energises Drumkee

Tue, 24th Nov 2020 21:30

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Gore Street Energy Storage Fund PLC - investor in utility-scale energy storage projects - Energises its 50 megawatt installed capacity Drumkee project in Northern Ireland. Drumkee becomes the largest energy storage project in Ireland. Expects its second 50 megawatt project, Mullavilly, to be energised in December. Both projects to be commissioned and operational in first quarter of 2021, taking portfolio's total installed capacity to 210 megawatts. "Notwithstanding the Covid lockdown and severe restrictions on movement, both project completion dates currently remain on schedule and budget."

----------

Martin Currie Global Portfolio Trust PLC - investment company focused on long-term returns in excess of the total return from the MSCI All Cos World index - Agrees draw down in full on unsecured three-year GBP30 million Royal Bank of Scotland International Ltd term loan with 1.181% fixed interest rate. Drawdown takes place on Tuesday. Loan represents around 10% of current net asset value.

----------

Immupharma PLC - London-based pharmaceutical company - Lind Global Macro Fund LP converts USD355,113 plus accrued unpaid interest of convertible security. This relates to convertible security deed from June 2020. Conversion price 11 pence per share, resulting in issue by Immupharma of 2.5 million shares.

----------

Helios Underwriting PLC - Lloyd's of London insurer - Receives valid acceptances for 252,843 open offer shares including applications under excess application facility. This represents 18% of open offer share available and raises GBP303,412. Non-Executive Chair Michael Cunningham and Non-Executive Director Andrew Christie subscribe for open offer entitlement of 6,053 and 2,392 open offer shares respectively.

----------

Block Energy PLC - exploration and production company focused on Georgia - Completes acquisition of Schlumberger Rustaveli Co Ltd and now holds licences for Georgian onshore blocks IX and XI. Company will now commence integration process and implement cost reduction plan. Has continues subsurface technical studies of Schlumberger Rustaveli assets "yielding economically attractive short and medium-term opportunities." Intends to apply for permits for workover and drilling programme across XI and West Rustavi licence areas.

----------

Uniphar PLC - healthcare services firm - Acquires RRD International, a US-based pharmaceutical advisory group that provides outsources consulting and execution services throughout early stages of product development. Purchase price includes upfront payment as well as contingent payment payable on achievement of earnings before interest, tax, depreciation, and amortisation-based targets. Acquisition expected to deliver return on capital employed in line with Uniphar's 12% to 15% target rate within three years. Further financial details not disclosed. Says: "acquisition will facilitate the growing requirement for Uniphar's delivery of US based expanded access programmes."

----------

Keras Resources PLC - mineral resource company - Notes that Chief Executive Russell Lamming has recently returned from Lome, Togo where he met with key government officials including Minister of Mines & Energy Mila Aziable and Minister of Investment Promotion Kayi Mivedor. Follow-up meetings also took place with state-owned Togo Invest Corp SA, which is helping assist with permitting process for the Nayega manganese mine in Northern Togo. Nayega is wholly owned by Kera's 85% owned Societe Generale de Mines subsidiary. Chief Executive Russell Lamming says: "Constructive meetings were undertaken with both the ministries of Mines and Energy and Investment Promotion during my recent trip to Togo; I expect to get feedback in the near term on what the pathway to final permitting at Nayega comprises."

----------

Lidco Group PLC - London-based hemodynamic monitoring company - As of Monday this week, Masimo has received valid acceptances in respect of 183.2 million Lidco shares, which it has acquired. These shares represent around a 75% stake in Lidco's existing issue share capital. Offer extended for 14 days and will stay open for acceptances until December 7. As announced November 2, Lidco has agreed to be acquired for GBP31.1 million, or 12 pence per share.

----------

FastForward Innovations Ltd - Guernsey-based closed-ended investment company - Notes update from hemp and CBD social commerce wellness company Yooma Corp, in which it holds a 10.65% stake. Yooma is launching clean CBD beauty brands MASK Skincare and Lab to Beauty ahead of the Black Friday and 12.12 China e-commerce events. These are being launched on BorderX Lab's China cross-border eCommerce app, Beyond. FastForward Chief Executive Ed McDermott: "We look forward to providing further updates regarding Yooma's commercial progress and its proposed merger with TSX quoted Globalive Technology Inc."

----------

Tern PLC - AIM-listed London-based investment firm specialising in internet of things - Portfolio company FVRVS Ltd secures GBP400,000 three-year contract with existing client. Client is an undisclosed "global pharmaceutical company". Contract to deliver recurring annual revenues over term from licences and support, enabling global rollout of the client's training solution using FundamentalVR's Fundamental Surgery virtual reality platform. Deal follows an initial GBP500,000 contract announced December 2019.

----------

Nippon Active Value Fund PLC - Japan-focused investment firm - Net asset value per share loses 0.5% to 105.03 pence over four months ended October 31 while share price reflects 10% discount to NAV. Since month end, both NAV per share and share price up, with NAV per share on November 16 being 109.33p and share price totalling 105p, with discount narrowed to 4%. Paul ffolkes Davis, chair of investment adviser Rising Sun Management, says: "There have been a myriad of recent articles on the changing landscape in Japan for corporate activity and consolidation of smaller, cash-rich companies. Certainly our initial engagement with [Ebara Jitsugyo] suggests these companies are susceptible to focused shareholder intervention - the auguries for NAVF's ongoing campaign look bright."

----------

Armadale Capital PLC - investment company focused on natural resource projects in Africa - Picks Xinhai Mineral EPC, part of Chinese Yantai Xinhai group, to begin metallurgical bulk test work as part of the first phase of front-end engineering design studies for its Tanzanian Mahenge graphite project. Aim of work is to provide enough data to confirm result underpinning definitive feasibility study and confirm the preferred flow sheet before FEED completion. First bulk samples received by Xinhai.

----------

Urban Exposure PLC - residential development firm and asset manager - Plans shortly to proceed with tender offer for up to GP65 million in value of Urban Exposure shares at 75 pence per share. Completion of this tender offer is subject to shareholder approval. As previously disclosed, tangible net asset value as at June 30 was 77p per share with tender price representing a 2.6% discount to tangible NAV but a 7.9% premium to mid-market price of 69.50p per share at close of business on Monday. Company's current cash balance is GBP81 million.

----------

CATCo Reinsurance Opportunities Fund Ltd - Investor focused on offering returns from investments linked to catastrophe reinsurance risks - Has been advised of additional release of side pocked investment capital totalling around USD8 million. This is set to be paid to the company in January 2021, with CATCo planning to use the funds for a six compulsory redemption of shares. Updates breakdown of payments to ordinary shareholders is approximately USD2 million, with around USD6 million to C shareholders. Notes that subsequent to approval, and including sixth redemption, it will have returned around USD271.3 million to shareholders through compulsory redemptions, dividend, a tender offer and share buybacks.

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
13 Dec 2019 12:12

ImmuPharma To List On Life Sciences Heavy Brussels Index

ImmuPharma To List On Life Sciences Heavy Brussels Index

Read more
11 Dec 2019 14:54

ImmuPharma says not looking to raise funds

(Sharecast News) - AIM-listed specialist drug discovery and development company ImmuPharma insisted on Wednesday that it is not looking to raise funds.

Read more
11 Dec 2019 14:03

ImmuPharma Confirms It Will Not Raise Funds Despite Share Price Rise

ImmuPharma Confirms It Will Not Raise Funds Despite Share Price Rise

Read more
28 Nov 2019 16:26

ImmuPharma shares soar as it teams up with Avion on Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced a licence and development agreement with Avion Pharmaceuticals on Thursday, for the exclusive rights to 'Lupuzor' in the United States.

Read more
28 Nov 2019 12:02

Immupharma Shares Take Off On Lupuzor US Licencing Deal With Avion

Immupharma Shares Take Off On Lupuzor US Licencing Deal With Avion

Read more
28 Nov 2019 07:28

ImmuPharma licenses lupus drug Lupuzor to Avion in the United States

LONDON, Nov 28 (Reuters) - British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals....

Read more
30 Sep 2019 10:40

ImmuPharma Loss Narrows Slightly, Focus On Lupuzor Regulatory Approval

ImmuPharma Loss Narrows Slightly, Focus On Lupuzor Regulatory Approval

Read more
28 Jun 2019 12:01

Immupharma Study Demonstrates Robust Safety Profile Of Lupuzor

(Alliance News) - Immupharma PLC on Friday reported analysis of the results from the study of Lupuzor, its lead programme for the potential breakthrough compound for Lupus, a potentially life drug

Read more
28 Jun 2019 10:27

ImmuPharma pleased with Lupuzor open-label study results

(Sharecast News) - Specialist drug discovery and development company ImmuPharma released the analysis of results from the open-label six month extension study from its original pivotal phase 3 trial of 'Lupuzor' on Friday.

Read more
26 Jun 2019 11:15

Immupharma raises ?2.66m from subscription agreement with institutional investor

(Sharecast News) - Drug discovery and development specialist Immupharma raised roughly £2.66m via a subscription agreement with institutional investor Lanstead Capital on Wednesday.

Read more
26 Jun 2019 10:14

Immupharma Raises GBP2.7 Million From Share Subscription With Lanstead

(Alliance News) - Immupharma PLC on Wednesday announced a 26.6 million share subscription to raise around GBP2.7 million at a price of 10 pence per share.The drug discovery and development

Read more
24 May 2019 11:47

Immupharma 2018 Loss Widens Amid Placing; Progresses On Pipeline

LONDON (Alliance News) - Drug development firm Immupharma PLC said Friday its 2018 loss widened amid share placing costs, whilst it continued to make "key" progress in its 2018, pretax a

Read more
7 May 2019 11:06

ImmuPharma Exploring European Listing For Combined French Businesses (ALLIPO)

LONDON (Alliance News) - ImmuPharma PLC is exploring the merger and possible separate listing of two French subsidiaries, it said Tuesday.Elro Pharma Sarl and Ureka Sarl are currently on a

Read more
1 Apr 2019 14:07

ImmuPharma Loses Exclusivity Period For Talks With Incanthera

LONDON (Alliance News) - ImmuPharma PLC on Monday said proposed partner Incanthera Ltd can now talk with other potential parties after an exclusivity period ended.In September, ImmuPharma a

Read more
14 Mar 2019 11:04

ImmuPharma struggles to convince investors in latest update

(Sharecast News) - Shares in ImmuPharma fell even further on Thursday, as the ailing drug development company struggled to give shareholders some reassurance about its future in an update.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.